Sacubitril/ Valsartan in Advanced Heart Failure: Is it Just a Matter of Contractility or are there Effects on the Pulmonary Circulation? A Real Life Monocentric Experience
Walter Serra, Rosario Bonura, Renato Alabrese & Marco Ferretti · Journal of Pharmaceutical Research International · 2021
Background: Sacubitril/valsartan (S/V), an angiotensin receptor neprilysin inhibitor (ARNI), is the first drug to demonstrate a mortality benefit in patients with chronic heart failure and reduced ejection fraction. S/v had a 20% reduction in the primary composite endpoint of car...
Open access
Research Article
10.9734/jpri/2021/v33i54A33740